Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Shuofeng Yuan
The COVID-19 pandemic is a serious problem of the new era. Acute respiratory distress syndrome (ARDS) and respiratory failure are the major lung diseases in COVID-19 patients. Although a COVID-19 vaccine is now available, there is still an urgent need to find potential treatments to reduce the impact of her COVID-19 on already sick patients. Several experimental drugs have been approved by the FDA, but their efficacy and possible side effects are unknown. An increasing number of studies worldwide investigating potential COVID-19-related therapies may help identify effective ARDS treatments. This review article first provides an overview of the immunopathology of ARDS. He then outlines the management of his COVID-19 patient requiring intensive care unit (ICU), focusing on current treatment strategies being evaluated in clinical trials for patients with COVID-19-induced ARDS.